2026-05-20T04:01:39Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/236212024-11-28T14:52:06Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16961col_20.500.12105_16967col_20.500.12105_16968col_20.500.12105_16969col_20.500.12105_16982col_20.500.12105_16983col_20.500.12105_16989
Repisalud author Bouzas, Cristina author Pastor, Rosario author Garcia, Silvia author Monserrat-Mesquida, Margalida author Martínez-González, Miguel Ángel author Salas-Salvado, Jordi author Corella, Dolores author Goday, Albert author Martínez, J Alfredo author Alonso-Gómez, Ángel M author Fernández-Barceló, Olga author Vioque, Jesus author Romaguera, Dora author Lopez-Miranda, José author Estruch, Ramon author Tinahones, Francisco J author Lapetra, José author Serra-Majem, Lluis author Riquelme-Gallego, Blanca author Martín-Sánchez, Vicente author Pintó, Xavier author Delgado-Rodriguez, Miguel author Matía, Pilar author Vidal, Josep author Cardenas-Salas, Jersy-Jair author Daimiel, Lidia author Ros, Emilio author Toledo, Estefanía author Manzanares, Josep M author Gonzalez-Monge, Inmaculada author Muñoz, Miguel-Ángel author Martinez-Urbistondo, Diego author Tojal-Sierra, Lucas author Muñoz-Bravo, Carlos author Miralles-Gisbert, Salvador author Martin, Marian author García-Ríos, Antonio author Castro-Barquero, Sara author Fernández-García, José Carlos author Santos-Lozano, José Manuel author Basterra-Gortari, F Javier author Gutiérrez-Carrasquilla, Liliana author Guillem-Saiz, Patricia author Satorres, Alba author Abete, Itziar author Sorto-Sanchez, Carolina author Díez-Espino, Javier author Babio, Nancy author Fito, Montserrat author Tur, Josep A 2024-10-09T06:33:47Z 2024-10-09T06:33:47Z 2023-05 Bouzas C, Pastor R, Garcia S, Monserrat-Mesquida M, Martínez-González MÁ, Salas-Salvadó J, et al. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. Biomed Pharmacother. 2023 May;161:114561. 10.1016/j.biopha.2023.114561 1950-6007 Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie https://hdl.handle.net/20.500.13003/18899 36934556 L2023388104 2-s2.0-85150299997 https://hdl.handle.net/20.500.12105/23621 Aims: To assess the comparative effects of glucagon-like peptide-1 receptor agonists (GLP-1RA), 4-dipeptidyl peptidase inhibitors (DPP-4I), and metformin treatment during one year on metabolic syndrome (MetS) components and severity in MetS patients. Methods: Prospective study (n = 6165 adults) within the frame of PREDIMED-Plus trial. The major end-point was changes on MetS components and severity after one- year treatment of GLP-1RA, DPP-4I, and metformin. Anthropometric measurements (weight, height and waist circumference), body mass index (BM), and blood pressure were registered. Blood samples were collected after overnight fasting. Plasma glucose, glycosylated hemoglobin (HbA1c), plasma triglycerides and cholesterol were measured. Dietary intakes as well as physical activity were assessed through validated questionnaires. Results: MetS parameters improved through time. The treated groups improved glycaemia compared with untreated (glycaemia ∆ untreated: -1.7 mg/dL(± 13.5); ∆ metformin: - 2.5(± 23.9) mg/dL; ∆ DPP-4I: - 4.5(± 42.6); mg/dL ∆ GLP-1RA: - 4.3(± 50.9) mg/dL; and HbA1c: ∆ untreated: 0.0(± 0.3) %; ∆ metformin: - 0.1(± 0.7) %; ∆ DPP-4I: - 0.1(± 1.0) %; ∆ GLP-1RA: - 0.2(± 1.2) %. Participants decreased BMI and waist circumference. GLP-1RA and DPP-4I participants registered the lowest decrease in BMI (∆ untreated: -0.8(± 1.6) kg/m2; ∆ metformin: - 0.8(± 1.5) kg/m2; ∆ DPP-4I: - 0.6(± 1.3) kg/m2; ∆ GLP-1RA: - 0.5(± 1.2) kg/m2. and their waist circumference (∆ untreated: -2.8(± 5.2) cm; ∆ metformin: - 2.6(± 15.2) cm; ∆ DPP-4I: - 2.1(± 4.8) cm; ∆ GLP-1RA: - 2.4(± 4.1) cm. Conclusion: In patients with MetS and healthy lifestyle intervention, those treated with GLP-1RA and DPP-4I obtained better glycemic profile. Anthropometric improvements were modest. eng Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome research article